The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models by Gril, Brunilde et al.
The B-Raf Status of Tumor Cells May Be a Significant
Determinant of Both Antitumor and Anti-Angiogenic
Effects of Pazopanib in Xenograft Tumor Models
Brunilde Gril
1*, Diane Palmieri
1, Yong Qian
1, Talha Anwar
1, Lilia Ileva
2, Marcelino Bernardo
2,3, Peter
Choyke
3, David J. Liewehr
4, Seth M. Steinberg
4, Patricia S. Steeg
1
1Women’s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America,
2Laboratory Animal Science Program, Science Applications International Corporation-Frederick, National Cancer Institute- Frederick, Frederick, Maryland, United States of
America, 3Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America, 4Biostatistics and Data
Management Section, Center for Cancer Research, National Cancer Research, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
Pazopanib is an FDA approved Vascular Endothelial Growth Factor Receptor inhibitor. We previously reported that it also
inhibits tumor cell B-Raf activity in an experimental brain metastatic setting. Here, we determine the effects of different B-
Raf genotypes on pazopanib efficacy, in terms of primary tumor growth and anti-angiogenesis. A panel of seven human
breast cancer and melanoma cell lines harboring different mutations in the Ras-Raf pathway was implanted orthotopically in
mice, and tumor growth, ERK1/2, MEK1/2 and AKT activation, and blood vessel density and permeability were analyzed.
Pazopanib was significantly inhibitory to xenografts expressing either exon 11 mutations of B-Raf, or HER2 activated wild
type B-Raf; no significant inhibition of a xenograft expressing the common V600E B-Raf mutation was observed. Decreased
pMEK staining in the responsive tumors confirmed that B-Raf was targeted by pazopanib. Interestingly, pazopanib
inhibition of tumor cell B-Raf also correlated with its anti-angiogenic activity, as quantified by vessel density and area. In
conclusion, using pazopanib, tumor B-Raf status was identified as a significant determinant of both tumor growth and
angiogenesis.
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Introduction
The validation of drug targets, particularly for multi-kinase
inhibitors, will be key to predicting sensitivity and developing
rational strategies to address resistance. Pazopanib is an anti-
angiogenic drug, binding to the ATP pockets of VEGFR1
(Vascular Endothelial Growth Factor Receptor), VEGFR2,
VEGFR3, PDGFRb (Platelet-Derived Growth Factor Receptor),
PDGFRa and c-kit in the low nanomolar range [1]. Its anti-
angiogenic activity was observed using corneal micropocket and
matrigel plug assays. Anti-tumor activity was demonstrated in
various human tumor xenografts [1]. In 2009 pazopanib was
approved by the FDA (Food and Drug Administration) for the
treatment of advanced renal cell carcinoma.
We recently identified B-Raf as a new, direct target for
pazopanib [2]. Pazopanib altered the in vitro signaling of a brain
metastatic derivative of MDA-MB-231 breast carcinoma cells,
231-BR, resulting in a reduction in the activity of the ERK
pathway despite the presence of both Ras and B-Raf mutations.
Enzymatic assays showed direct inhibition of B-Raf by pazopanib.
In vivo, pazopanib prevented experimental brain metastases by
231-BR cells or HER2 transfectants of MCF7 breast carcinoma
cells (selected for brain tropism, (MCF7-HER2-BR3)) by 73% and
55%, respectively; a concomitant reduction in pERK activity was
observed, suggesting that B-Raf was a drug target in vivo. No anti-
angiogenic response was observed in the brain metastasis models,
which may reflect the highly vascular nature of the brain where co-
option of existing blood vessels is predicted to occur [3,4,5].
B-Raf is a serine/threonine kinase responsible for the activation
of the MEK-ERK signaling pathway downstream of the Ras
GTPase. Both Ras and Raf are gene families with multiple
interactions among members resulting in complex signaling [6].
Numerous drugs have been developed to target Raf, in particular
B-Raf activated by a V600E mutation common in melanoma
[7,8,9,10]. A series of recent reports extensively studied the
complex mechanisms of action of several Raf inhibitors such as
Sorafenib, PLX4032 and PLX4720 [7,8,9,11,12,13]. These
reports demonstrate potential adverse effects of Raf inhibitors
depending on the tumor genotype, such as the paradoxical
activation of C-Raf and the downstream MEK-ERK pathway in
tumor cells expressing mutant Ras.
The effect of pazopanib on the spectrum of B-Raf mutations
remains to be determined, as well as the relative contributions of
its various targets to its anti-tumor effects. In the current report, a
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was used to further define the spectrum of pazopanib activity both
in vitro and in vivo. The data point to a unique pattern of in vivo
selective activity for pazopanib relative to B-Raf signaling. The
data also identify a previously unrecognized association between
tumor cell B-Raf status and anti-angiogenic activity in vivo.
Materials and Methods
Drugs and cell lines
Pazopanib was provided by GlaxoSmithKline. Pazopanib
powder was reconstituted in DMSO and stored at 280uC
(20 mM stock). For in vivo experiments the vehicle was 0.5%
hydroxypropylmethylcellulose with 0.1% Tween 80 in water. The
human MDA-MB-231 BR ‘‘brain seeking’’ (231-BR) cell line and
its culture were previously described [14,15]. MCF7 and MCF7-
HER2 (HER2 accession number: NM004448) were kindly
provided by Dr. Dennis Slamon (University of California Los
Angeles, Los Angeles, CA, USA) and maintained in RPMI-1640
(Invitrogen) supplemented with 10% FBS and 1% penicillin-
streptomycin solution. SKMEL2 and SKMEL28 were kindly
provided by Dr. Michael Gottesman (National Cancer Institute,
NIH, Bethesda, MD) and maintained in RPMI supplemented with
10% FBS, penicillin-streptomycin solution and 2 mM glutamine
(Invitrogen). WM3899 and WM3918 melanoma cell lines, isolated
from patients, were provided by Dr. Meenhard Herlyn (The
Wistar Institute of Anatomy and Biology, Philadelphia, PA). These
cell lines were maintained in Tu2% growth media (80%
MCDB153, 20% Leibovitz’s L-15, 2% FBS, 5 mg/ml Bovine
Insulin and 1.68 mM CaCl2).
In vitro experiments
Standard procedures were used for immunoblot analysis and
viability assays, which were described previously [2]. For the
immunoblot analysis, total and pERK1/2, PDGFRa and b,B -
Raf, VEGFR3 and c-kit antibodies were obtained from Cell
Signaling Technology and used at a 1:1000 dilution. PlGF
(Placenta Growth Factor), VEGF, and VEGFR1 antibodies were
obtained from Santa Cruz Biotechnology and used at 1:500. The
exposure time for the western blots was optimized to avoid
saturation of the strongest signals. The B-Raf kinase assay is
described in the Material and Methods S1. For B-Raf siRNA
transfection, siRNA constructs were purchase as Duplexed
Stealth
TM RNAi (Invitrogen). The protocol and siRNA sequences
were described previously [2]. The protocol for B-Raf siRNA
transfection is described in the Material and Methods S2. For the
cell viability assay, cell lines were plated at a density of 5,000 cells/
well in 24-well plates and incubated overnight to allow cells to
adhere. Tumor cell lines were maintained in 10% FBS and treated
with increasing concentrations of pazopanib (1–10 mM) or with
DMSO as a control, for 96 hours. The number of viable cells was
determined by counting, with a hemocytometer, trypsinized cells
that excluded trypan blue dye. A second method was also
performed, using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide (MTT; Sigma) in a 96-well plate format. Results
are representative of three independent experiments, each
performed in triplicate or quintuplicate.
Primary tumor formation
Animal experiments were conducted under an approved
Animal Use Agreement with the NCI. For the breast cancer cell
lines (231-BR, MCF7 and MCF7-HER2), 5- to 7-week-old female
athymic nude mice (nu/nu) (Charles River Laboratories) were
anesthetized under isoflurane/O2 and 5610
6 cells were inoculated
in the fourth mammary fat pad. One day before MCF7 and
MCF7-HER2 implantation then, once a week thereafter, mice
were injected with 1.5 mg/kg 17 b-estradiol (Innovative Research
of America) to promote tumor cell growth. There were two
independent experiments performed on the breast cancer cell lines
(representative results are presented). For the melanoma cell lines
(SKMEL28, SKMEL2, WM3899 and WM3918), 5- to 7-week-old
female athymic nude mice (nu/nu) were injected subcutaneously
into one flank. Cells were injected in 100 mL of matrigel (BD
Biosciences) (WM3899: 500,000 cells per mouse, WM3918:
1610
6, SKMEL28: 5610
6, SKMEL2: 5610
6).
For each experiment, 7–10 mice were used in each treatment
group. Treatment started when the average tumor size was
approximately 100 mm
3 and was administered by oral gavage
twice daily. During treatment, measurements of the tumor size
and mouse weight were calculated twice weekly. For tumor
volume determination: Two-dimensional measurements were
taken twice per week with a caliper and tumor volume (V)
calculated using the following formula: V=a6b
260.52, where ‘‘a’’
is the longest diameter, ‘‘b’’ is the shortest one, and 0.52 is a
constant to calculate the volume of an ellipsoid.
Immunohistochemistry and Immunofluoresence
The protocols were described previously [2]. For each primary
tumor, positively stained cells for pERK1/2, pMEK1/2 and
pAKT were counted at 4006 magnification in three different
‘‘hot-spot’’ fields per tumor. After CD31 staining, the number of
blood vessels and percentage of area covered by blood vessel were
measured at 1006 magnification in three different ‘‘hot-spot’’
fields per tumor.
In Vivo DCE-MRI
DCE-MRI (Dynamic contrast enhanced-magnetic resonance
imaging) was performed by taking a series of 60 3D T1-weighted
FFE dynamic images (TR=11 ms, TE=2.3 ms, matrix
=5126512, FOV=80680 mm, slices=18, thickness=1 mm,
scan time=45 sec) in the coronal plane. Magnevist (Bayer
HealthCare Pharmaceuticals,Wayne, NJ) was administrated at a
concentration of 0.2 mmol Gd/kg mouse in the tail IV as a bolus
injection (150 mL/min) after the first dynamic scan. The DCE-MRI
analyses are described in the Material and Methods S3.
Statistical analysis
Methods are described in Material and Methods S4.
Results
Characterization of the breast cancer and melanoma cell
lines used
We previously identified a B-Raf inhibitory activity for the anti-
angiogenic drug pazopanib [2]. The activity of pazopanib against
the spectrum of B-Raf mutations, and its relationship to other
known targets remains unknown. To investigate these questions, a
panel of seven human breast carcinoma and melanoma cell lines
was examined for pazopanib responsiveness in vitro and in vivo.
Table 1 lists the seven cell lines, their reported Raf pathway
mutational status, and their expression of relevant pazopanib
pathway components, determined by western blot (data not
shown). The breast cancer cell lines included the brain seeking
variant of the ‘‘triple negative’’ MDA-MB-231 cell line, 231-BR,
the estrogen receptor positive MCF7 cell line and the MCF7 line
transfected with HER2. The melanoma cell lines included the
WM3899 cell line, the WM3918 line, the SKMEL28 line and the
SKMEL2 line. As shown in Table 1, these cell lines harbor
Tumor B-Raf Status and Pazopanib Activity
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vs. various mutations), and in regard to expression of the number
and level of other established pazopanib targets (PDGFRb/a,
VEGFR1/3 and c-kit).
Pazopanib inhibition of B-Raf is associated with its anti-
growth activity in vitro
Pazopanib was tested for inhibition of tumor cell viability. Two
independent assays were performed to determine the IC50 of
pazopanib on each cell line: a trypan blue exclusion assay (Table 1)
and an MTT assay (Table S1), with concordant trends. To
determine if the B-Raf pathway was modulated by pazopanib,
each cell line was treated with vehicle or 0.5–5 mM pazopanib and
the pERK1/2 status determined by western blot (Fig. 1). To
eliminate the effect of a potential feedback loop mechanism from
occurring in cells and altering pERK1/2 levels, a B-Raf kinase
assay was also performed on lysates from each cell line (Fig. S1).
The cell lines most sensitive to growth inhibition by pazopanib
were 231-BR, WM3899 and WM3918 lines, with an IC50 of 1.22–
2.18 mM (Table 1). Both 231-BR and WM3899 harbor a mutation
in exon 11 of B-Raf and were the only cell lines to show a clear
decrease in pERK1/2 at all three concentrations of pazopanib
(Fig. 1) and a decrease in pMEK1 in the lysate kinase assay (Fig.
S1). The other pazopanib sensitive cell line, WM3918, expresses a
wild type Ras-Raf-ERK1/2 pathway; however, it also expresses
three of the previously established pazopanib targets (VEGFR1,
VEGFR3 and PDGFRb). Expression of these targets potentially
accounts for its sensitivity to pazopanib. When the WM3918 cell
line was treated with pazopanib an increase in pERK1/2 was
detected at the highest concentration used (Fig. 1). Furthermore
the kinase assay for this cell line showed no inhibition of pMEK1
(Fig. S1), indicating that pazopanib growth inhibition was
independent of B-Raf.
HER2 overexpression by the MCF7 cells, which constitutively
activates the B-Raf pathway, altered pazopanib sensitivity. When
HER2 was over-expressed in MCF7 cells, the IC50 decreased from
6.29 to 3.96 mM. In parental MCF7 cells, pazopanib increased
pERK1/2 expression. However the transfection of HER2 into this
cell line changed the dynamics of the pathway as shown by a slight
decrease in pERK1/2 after pazopanib treatment (Fig. 1), and a
slight decrease in pMEK1 in the kinase assay (Fig. S1), concordant
with growth inhibition.
The two cell lines which were the least sensitive to the growth
inhibitory effect of pazopanib, were the melanoma cell lines:
SKMEL2 that expresses mutant N-Ras and the SKMEL28 line
that harbors the V600E mutation for B-Raf (IC50 5.13 and
Table 1. In vitro growth inhibition by pazopanib on breast carcinoma and melanoma cell lines expressing different genotypes in
the Ras-Raf-ERK1/2 pathway
*.
Pazopanib targets
I
Cell Lines B-Raf Status Ras Status Pazopanib IC50 (mM)
{ V1
1 V3 Pa Pa c-kit
231-BR G464V G13D (K-Ras) 1.22 + 2 + 22
MCF7-HER2 WT WT 3.96 +/22 2 2 2
MCF7 WT WT 6.29 +/22 2 2 2
WM3899 G469V WT 2.18 2 +/22 2 2
WM3918 WT WT 2.13 ++ /2 + 22
SKMEL28 V600E WT 6.13 2 + 222
SKMEL2 WT Q61R (N-Ras) 5.13 +/2 +/22 2 2
*Genotypes for MDA-MB-231 and MCF7 [47]; genotypes for WM3899 and WM3918 personal communication by Dr. Meenhard Herlyn; genotypes for SKMEL2 and
SKMEL28 [48].
{IC50 measured using a trypan blue exclusion cell viability assay 96 h after pazopanib treatment.
IDetermined by western blot analysis. (+) when a clear band appeared in less than one minute of exposure; (2) when no signal at all appeared after more than 30 min
of exposure; (+/2) when a faint band was observed, after 20 min of exposure.
1Pa, PDGFRa;P b, PDGFRb; V1, VEGFR1; V3, VEGFR3; WT, Wild Type.
doi:10.1371/journal.pone.0025625.t001
Figure 1. Effect of pazopanib on ERK activation. Tumor cells were serum starved overnight and subsequently treated with pazopanib or DMSO
for 24 hours. After treatment, cells were stimulated with 10 ng/mL VEGF for 10 minutes, and cell lysates were analyzed by immunoblot for pERK1/2.
The data shown are representative of two conducted experiments.
doi:10.1371/journal.pone.0025625.g001
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the SKMEL28 cell line (Fig. 1) nor on pMEK1 in cell lysate (Fig.
S1). In the SKMEL2 cell line, pazopanib increased pERK1/2
expression at a low concentration but shut down ERK1/2
activation at a higher dose (Fig. 1); no effect of pazopanib was
observed on pMEK1 level in the kinase assay (Fig. S1).
Taken together, the data show two-to- three-fold preferential
growth inhibition by pazopanib for tumor cell lines harboring
mutations in exon 11 of B-Raf or where HER2 activated wild type
B-Raf. Growth inhibition was associated with reduced ERK1/2
phosphorylation and MEK1 phosphorylation in the two cell lines
harboring mutations in exon 11 of B-Raf. A lesser degree of
growth inhibition was observed for MCF7 cells transfected with
HER2, which was accompanied by a less pronounced decrease in
pERK1/2 and pMEK1 expression. The combination of pazopa-
nib targets, as evidenced in the WM3918 cell line (expressing
VEGFR1, VEGFR3 and PDGFRb), resulted in growth inhibition
independent of B-Raf.
To further investigate the correlation between B-Raf status and
pazopanib efficacy, 231-BR cells were transfected with siRNA
against B-Raf. At 48 h after siRNA transfection, which corre-
sponded to the time point when pazopanib treatment was started,
the percentage decrease in B-Raf protein expression for the three
experiments conducted was 23–46% and 65–74%, for constructs
#1 and #2, respectively. At 144 h after siRNA, which
corresponded to 96 h of pazopanib treatment, B-Raf protein
knockdown was less pronounced, 3 to 58% for construct #1 and
76 to 89% for construct #2 (Fig. S2 A–B). After 96 h of pazopanib
exposure, an MTT assay was performed on the control and B-Raf
knockdown transfectants. The B-Raf siRNA construct #2
produced a significant 48% decrease in cell viability compared
to cells transfected by the non targeted siRNA (p=0.010).
However, no change in cell viability was observed for construct
#1 (Fig. S2C), likely due to insufficient knock down of B-Raf. The
two B-Raf siRNA constructs also produced different cellular
responses after pazopanib treatment. A significant decrease in the
pazopanib IC50 was observed in the cells transfected with
construct #2 compared to the controls (3.85 compared to
4.9 mM, respectively (p=0.024)). However, in cells transfected
with construct #1, B-Raf was re-expressed after pazopanib
treatment, which likely resulted in lesser sensitivity to pazopanib
compared to the control (IC50 of 6.87 compared to 4.9 mM,
respectively (p=0.008)). A representative experiment is shown on
Figure S2D. Overall, the significant differences in pazopanib
sensitivity contingent on the level of B-Raf expression confirmed a
key role of B-Raf protein in pazopanib’s mechanism of action.
Pazopanib inhibition of primary tumor growth
Primary tumor growth experiments were conducted to
determine if B-Raf status also predicted in vivo sensitivity to
pazopanib. It was also of interest to determine if the two- to three-
fold differences in IC50 observed in vitro translated in to significant
trends in vivo. The breast cancer cell lines listed in Table 1 were
implanted in the mammary fat pad, and the four melanoma cell
lines were injected subcutaneously. Mice were randomly chosen to
receive vehicle, 30 mg/kg or 100 mg/kg pazopanib, twice daily by
oral gavage, once tumors reached a mean of approximately
100 mm
3 (Fig. 2). In brief, the order of sensitivity of tumor growth
inhibition by pazopanib was 231-BR, WM3899,
WM3918.MCF7-HER2&SKMEL2, SKMEL28, MCF7. This
trend is comparable to the in vitro sensitivity of each line to
pazopanib.
Primary tumor growth produced by the 231-BR cell line, which
contains an exon 11 mutation of B-Raf, was maximally sensitive to
pazopanib in vitro and significantly inhibited by pazopanib 9 days
after treatment with the highest drug dose (p=0.009). Three days
later, the 30 and 100 mg/kg doses induced 40% and 59% tumor
growth inhibition, respectively (p=0.030 (this p value represents a
strong trend) and p=0.002, respectively). The WM3899 cell line,
which harbors a similar exon 11 B-Raf mutation and was sensitive
to pazopanib in vitro, was also highly sensitive to pazopanib in
vivo, with 62% and 67% decreases in tumor size 7 days after
treatment at 30 and 100 mg/kg drug, respectively (p=0.002 and
p=0.0002, respectively). Ten days after starting drug treatment,
both doses continued to significantly inhibit tumor growth, and at
day 14 of treatment the tumor growth inhibition was 69% and
75% at 30 mg/kg and 100 mg/kg, respectively (p=0.0002 and
p,0.0001, respectively).
The MCF7 cell line, which was less sensitive to pazopanib in
vitro, exhibited no statistically significant differences in tumor size
through 13 days of treatment. For the MCF7-HER2 cell line,
which was 37% more sensitive to pazopanib in vitro, an inhibition
of tumor growth at the highest drug dose was observed 9 days after
starting treatment (p=0.042 (this p value represents a strong
trend)); both doses were inhibitory 4 days later with 45% and 47%
tumor growth inhibition at 30 and 100 mg/kg, respectively
(p=0.019 (this p value represents a strong trend) p=0.008,
respectively).
The WM3918 cell line was significantly inhibited by the highest
dose of pazopanib 10 days after treatment (p=0.0001). Four days
later, the highest dose still significantly inhibited the tumor growth
(65% of tumor inhibition, p,0.0001). This was the only cell line
that expressed three of the established targets of pazopanib, which
provides an explanation for its sensitivity to the drug despite the
expression of a normal B-Raf pathway.
In contrast, tumor cell lines with mutations shown to be less
sensitive to pazopanib inhibition in vitro exhibited less sensitivity
to the drug in vivo. For the SKMEL28 melanoma cell line (V600E
B-Raf mutation), a modest but significant decrease in tumor size
was observed after nine days of treatment, however, none of the
doses maintained significant efficacy four days later. For the
SKMEL2 cell line, harboring an N-Ras mutation, no efficacy was
observed. In summary, the trends in growth inhibition by
pazopanib in cell culture were directly correlated with, and
magnified in, tumorigenesis in vivo.
Pazopanib inhibition of the B-Raf pathway in vivo
To confirm that B-Raf was targeted in the pazopanib-sensitive
primary tumors, the phosphorylation levels of the B-Raf
downstream targets MEK1/2 and ERK1/2 was determined by
immunohistochemistry (Fig. 3 and Fig. S3). For each cell line
xenograft, one tissue slide per tumor and five mice per treatment
group (vehicle, 30 and 100 mg/kg) were stained for pMEK1/2
and pERK1/2. In each slide the number of positive cells was
quantified, with the mean for the five mice reported on Figure 3 at
the bottom right of each representative photograph.
In general, cell lines with exon 11 B-Raf mutations or HER2
activation of wild type B-Raf showed evidence of Raf pathway
inhibition in vivo. A 44–65% decrease in pERK1/2 staining and a
30–63% decrease in pMEK1/2 were observed in the pazopanib
sensitive 231-BR, MCF7-HER2 and WM3899 tumors treated
with 100 mg/kg drug, with a trend at 30 mg/kg. The effect of
pazopanib on the tumor growth of the WM3918 cell line was
confirmed to not be associated with B-Raf targeting as a significant
decrease of pMEK1/2 and pERK1/2 was not observed at any
drug dose. The inhibition in tumor growth was therefore probably
due to the inhibition of the three established targets (VEGFR1,
VEGFR3, and PDGFRb), leading to the inactivation of alternative
Tumor B-Raf Status and Pazopanib Activity
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25625Figure 2. Effect of pazopanib on primary tumor growth of breast cancer and melanoma cell lines. Breast cancer lines were implanted in
the mammary fat pad, while melanoma cells were implanted subcutaneously. Mice were randomly chosen to receive vehicle or 30 or 100 mg/kg
pazopanib, twice daily for 10–14 days. Tumor size was measured twice weekly. Arrows indicate when treatment started. P values are shown for the
tumors in which the decrease in tumor size achieved significance (p,0.01) at a given dose of pazopanib. The results shown for 231-BR, MCF7 and
MCF7-HER2 cell lines are representative of two experiments. Raw data means and SEM are presented; analysis was performed on cubed root
transformed data.
doi:10.1371/journal.pone.0025625.g002
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tumor growth. No activation of ERK1/2 was observed in vivo, as
was seen in vitro on Figure 1, suggesting the potential role of the
microenvironment in vivo. In contrast, a significant decrease in
pMEK1/2 was observed in MCF7 tumors treated with 30 mg/kg
pazopanib, but it was not accompanied by a similar decrease in
pERK1/2 staining. The remaining tumors did not show any
statistically significant decrease in the number of positively stained
cells in the 100 mg/kg treatment group for either of the two
markers. None of the tumors exhibited decreased pAKT at any
drug dose tested (Fig. 3 and Fig. S3). This trend supports the
selectivity of pazopanib for the B-Raf pathway in vivo.
The anti-angiogenic activity of pazopanib is associated
with tumor cell B-Raf inhibition
Pazopanib is well characterized as an anti-angiogenic drug.
Normal endothelial cells express VEGFR2 and should have a wild
type B-Raf pathway. We therefore hypothesized that pazopanib
would exert comparable anti-angiogenic effects on each of the
primary tumor xenografts. To test this, measurements of CD31+
vascular density and area of tumor covered by vasculature were
determined on the primary tumors (Fig. 4A–B and Fig. S4).
Figure 4C and Figure S4 present representative photographs of
CD31 staining.
Interestingly, a significant decrease in blood vessel density and
percentage of area covered by blood vessels was observed in the
pazopanib-sensitive tumors: 231-BR, MCF7-HER2 and WM3899
(p,0.01). Again, these represent the cell lines with either an exon
11 B-Raf mutation or HER2 activation of wild type B-Raf. An
anti-angiogenic effect of pazopanib was also observed in the
WM3918 tumor. This cell line harbors a normal B-Raf pathway;
however, it remained sensitive to pazopanib as shown by the
decrease in blood vessel density, probably due to the expression of
three of the established targets of pazopanib, leading to the
disruption of downstream pathways other than ERK1/2. A
significant decrease in blood vessel density was observed in the
MCF7 tumor treated with 30 mg/kg but no significant difference
was observed in the percentage of blood vessel coverage. Nor was
the blood vessel density decrease maintained at the 100 mg/kg
dose. No decrease in blood vessel density or percentage of area
covered by blood vessels was observed in the SKMEL28 or
SKMEL2 cell lines.
To further explore this unexpected trend, another aspect of
VEGFR activity was examined, blood vessel permeability.
Primary tumors were imaged by DCE-MRI. Indeed, blood vessels
in tumors were described as structurally and functionally abnormal
[16]. They are more dilated, tortuous and more permeable than
normal blood vessels. VEGF, the best known angiogenic molecule,
induces survival and proliferation of endothelial cells and increases
vascular permeability [17,18,19]. DCE-MRI is a widely used
noninvasive quantitative method of investigating vascular structure
and function by tracking the pharmacokinetics of injected contrast
Figure 3. Pazopanib inhibition of primary tumor growth correlates with B-Raf inhibition. Tumor cell lines and the B-Raf genotypes are
listed. Representative photographs of pERK1/2, pMEK1/2 and pAKT immunostaining are shown for the vehicle and the 100 mg/kg pazopanib treated
groups. The mean number of positive cells 6 SEM is shown on each representative image. Asterisks (*) indicate a statistically significant difference
between the pazopanib and vehicle treated group (p,0.01). (See Figure S3 for the 30 mg/kg dose data).
doi:10.1371/journal.pone.0025625.g003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25625Figure 4. Anti-angiogenic effect of pazopanib on primary tumor xenografts correlates with B-Raf status. Panel A: Breast cancer
xenografts. Panel B- Melanoma xenografts. In each panel the top graph represents the mean number of blood vessels per tumor section (n=5 mice)
6 SEM and the bottom graph represents the percentage of area covered by blood vessels (n=5 mice) 6 SEM for the vehicle treated group, the
30 mg/kg group and the 100 mg/kg group. Panel C: Representative photographs of CD31 staining for vehicle and 100 mg/kg treatment groups.
Asterisks (*) indicate a statistically significant difference between the pazopanib and vehicle treated groups (p,0.01). (See Figure S4 for
representative photographs of CD31 staining).
doi:10.1371/journal.pone.0025625.g004
Tumor B-Raf Status and Pazopanib Activity
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photographs and K
trans calculations are presented on Figure 5.
Parametric color maps generated by analysis of DCE-MRI
illustrate that most of the tumor vascularity was found in the
periphery. The only cell line that exhibited a decrease in K-trans
was the 231-BR cell line (p=0.027). The remaining cell lines
demonstrated smaller changes in the mean K
trans values. No
significant changes in Kep were noted (data not shown). Thus, the
only cell line showing significantly reduced vascular permeability
also exhibited an exon 11 B-Raf mutation.
Potential anti-angiogenic factors downstream B-Raf
The three most sensitive tumor cell lines, evidenced by decrease
in tumor growth, blood vessel density and pERK1/2 in response
to pazopanib, were the 231-BR, MCF7-HER2, and WM3899 cell
lines. These cell lines harbor either B-Raf mutations in exon 11 or
HER2 overexpression-activated wild type B-Raf. Based on the
association between specific B-Raf status, pERK1/2 decrease and
a consistent blood vessel density decrease, we hypothesized that
the B-Raf pathway may regulate angiogenic factor production.
The 231-BR and MCF7-HER2 cell lines were transfected with
two different siRNA constructs against B-Raf, and the expression
of two major angiogenic growth factors was analyzed by western
blot. As controls, the cell lines were transfected with a scramble
RNA or were treated with the transfection agent only (Fig. S5).
The two siRNA B-Raf constructs decreased the expression level of
B-Raf; however no effect on VEGF expression level was observed;
a decrease in PlGF was observed only in the 231-BR cell line. To
investigate additional angiogenic factors, a protein array for
angiogenic related-proteins (covering 55 angiogenesis related
proteins) was performed. The angiogenic protein array did not
show any detectable difference between B-Raf knock down and
control cell lines. However as previously mentioned, the knock
down of B-Raf protein was incomplete and the remaining B-Raf
expression level may have been sufficient to maintain the integrity
of downstream pathways.
Discussion
While developed to inhibit VEGFR2 signaling in endothelial
cells, pazopanib also inhibits VEGFR1 and 3, PDGFR a and b,
and c-kit. Recently a B-Raf inhibitory activity was reported for
pazopanib and shown to be operative in its brain metastasis
preventative efficacy in two models of HER2 driven breast cancer
metastasis to the brain. Herein, we investigated the effects of
pazopanib on a panel of seven breast carcinoma and melanoma
xenografts to determine the relative contribution of B-Raf versus
other targets to its anti-tumor activity (Fig. 6).
Three conclusions are evident from this work. First, pazopanib
was directly inhibitory to tumor cells in vitro, in addition to its
reported anti-angiogenic effects. These data confirm findings
previously reported for lung cancer cells and multiple myeloma
[20,21]. In vitro, two patterns emerged among the seven cell lines
for sensitivity to pazopanib: (1) a favorable B-Raf status. B-Raf
exon 11 mutations were found in the sensitive 231-BR and
WM3899 cell lines while HER2 overexpression occurred in the
sensitive MCF7-HER2 cell line, consistent with previously
reported enzymatic inhibition assays [2], and; (2) expression of
multiple targets, exemplified in the WM3918 cell line expressing
PDGFRb, VEGFR1 and low levels of VEGFR3, but a normal B-
Raf. Differences in growth inhibition in vitro were only two-to
three-fold, but correlated with magnified, statistically significant
inhibition of xenograft growth in vivo. B-Raf inhibition was
confirmed in the sensitive cell lines in vitro and in vivo by
inhibition of MEK phosphorylation.
Conversely, relative insensitivity to pazopanib was detected in
the B-Raf V600E mutated melanoma line SKMEL28 and the
SKMEL2 melanoma cell line harboring an N-Ras mutation. In
data not shown, a second melanoma cell line expressing mutant N-
Ras, WM1366, was also relatively resistant to pazopanib with an
IC50 of 8 mM. Also, two other melanoma cell lines expressing the
V600E B-Raf mutation, WM278 and MALMEL, showed a
relatively high IC50 similar to SKMEL28 (9 mM); in vivo tests were
not conducted. Dumaz et al. reported that when Ras is mutated in
melanoma cell lines, tumor cells switch their signaling to C-Raf to
activate the MEK/ERK pathway, forgoing B-Raf [22], which
may be operative.
Figure 5. Effect of pazopanib on blood vessel permeability of
breast and melanoma cell xenografts. Dynamic Contrast- En-
hanced Magnetic Resonance Imaging (DCE-MRI) was performed on 5
mice per group at the end point. Representative photographs and K
trans
calculations are presented.
doi:10.1371/journal.pone.0025625.g005
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distinct from other reported Raf inhibitors [7,8,9,11,12]. The lack
of activity towards the common V600E mutated B-Raf suggests
limited B-Raf directed activity in melanoma. The exon 11
mutations found in the pazopanib-sensitive 231-BR and
WM3899 cell lines are relatively rare in cancer [23,24]. Pazopanib
was significantly more inhibitory to a HER2 transfectant of MCF7
breast carcinoma cells in vivo than the parental cell line,
confirming that HER2 activation of wild type B-Raf is a sensitive
target for this drug. The B-Raf inhibitor PLX4032 was reported to
increase ERK signaling in the HER2+ SKBR3 cell line [9],
confirming the differences between these drugs. It will be of
interest to determine if overexpression of other receptor tyrosine
kinases also confers sensitivity to pazopanib via consistent
stimulation of wild type B-Raf.
In cells harboring a wild type genotype in the Ras-Raf pathway,
Raf inhibitors induced a paradoxical activation of the downstream
MEK-ERK pathway, due to transactivation of C-Raf
[7,8,9,11,12,13]. However, even if pazopanib induced an increase
in the pERK1/2 level in the MCF7 and WM3918 cell lines in
vitro, it did not induce any paradoxical activation of the ERK
pathway in vivo. These results showed that the mechanism of
action of pazopanib appeared to be different from the mechanism
of action of other previously studied Raf inhibitors.
We asked whether previous preclinical and clinical research on
pazopanib is consistent with the B-Raf pattern observed herein.
Pazopanib has been reported to be growth inhibitory in other
preclinical xenograft models [1,21,25]. It is interesting to note that
the least sensitive xenograft in that series was the A375P
melanoma, which harbors a V600E mutation in B-Raf [26]. In
the clinic, pazopanib produced responses in renal, thyroid,
cervical, ovarian and non-small cell lung carcinomas and soft
tissue sarcoma [27,28,29,30,31,32,33,34]. Based on the available
data, the V600E mutation is unlikely to be a common driver of B-
Raf activation clinically. Of the potential pathway components in
the literature, K-Ras mutation, which occurred in 231-BR cells
and constitutively activates B-Raf, is found in lung, cervical and
ovarian carcinomas [35,36,37]; renal carcinomas demonstrate
both K-Ras mutation and amplification [38,39]. HER2 amplifi-
cation is found in ,20–25% of breast tumors. Pazopanib has been
tested in HER2 overexpressing breast cancer in combination with
lapatinib based on the known highly angiogenic nature of these
tumors [40], but B-Raf activation may also contribute to the
observed efficacy. HER2 amplification is also present in a fraction
of other tumor types. Conversely, the clinical literature contains
hints that the V600E B-Raf mutation may not confer pazopanib
sensitivity. In a radioiodine-refractory metastatic differentiated
thyroid cancer cohort, 73% of patients with disease control of $1
year had follicular tumors [29]. While V600E B-Raf mutations are
common in thyroid cancer, follicular thyroid cancers are negative
for this mutation [41]. While fragmentary, the data are consistent
with the conclusion that B-Raf activation via the pathways
described herein to mediate pazopanib sensitivity may contribute
to its clinical efficacy.
Third, the greatest surprise in the present series of experiments
was that the anti-angiogenic activity of pazopanib was not
equivalent in all xenografts, but correlated with tumor B-Raf
pathway sensitivity. Thus, the 231-BR, MCF7-HER2, WM3899
and WM3918 cell lines exhibiting either exon 11 mutations,
HER2 overexpression, or multiple pazopanib targets were the only
xenografts with a significant anti-angiogenic response to pazopa-
nib. This trend held when angiogenesis was measured by
microvessel density or area covered by vasculature. An exception
to this conclusion was an analysis of permeability by DCE-MRI,
which may reflect the late time point used where only a rim of
tumor was analyzed. The data indicate that tumor cell B-Raf plays
a significant role in angiogenesis.
The decrease in blood vessel density in response to pazopanib is
unlikely to be explained by a simple decrease in tumor size. For
example, MCF7 tumors treated with 100 mg/kg pazopanib
Figure 6. Schematic of pazopanib signaling pathways. The standard receptor tyrosine kinase activation of the ERK pathway is shown.
Pazopanib sensitive alterations, including HER2 overexpression and B-Raf exon 11 mutations, are shown on the right in red. Insensitive alterations are
shown on the left in blue. Tumor cell lines featuring each alteration are named.
doi:10.1371/journal.pone.0025625.g006
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3 at the end point with a blood vessel
density of 70614; in the MCF7 transfected with HER2 xenografts
similarly treated, tumor size at the end point was larger
(300 mm
3), however the blood vessel density was lower (5767).
Similarly, the WM3899 (B-Raf mutation in the exon 11) and the
SKMEL28 tumors were both of comparable size at the
experimental end point; however, the blood vessel density in the
WM3899 tumor was half of the vessel density in the SKMEL28
tumors (2167 versus 5067).
A second hypothesis to explain the data was that the tumor cell
B-Raf pathway controlled the production of angiogenic cytokines.
The Ras-Raf-MEK-ERK pathway induces VEGF expression
directly or indirectly [42,43,44,45,46]. Herein, knockdown of B-
Raf by siRNA in two cell lines failed to consistently modulate
VEGF, PlGF or an array of angiogenic related proteins. However,
this result may not be sufficient to exclude the involvement of
angiogenic pathways downstream B-Raf because the angiogenesis
array was performed in vitro and therefore could not mimic the in
vivo direct interactions between tumor cells and endothelial cells.
Moreover, a better knockdown of B-Raf may be necessary to block
potential downstream angiogenic pathways.
Our data suggest that several markers, including B-Raf status
(pMEK/pERK), Ras mutation and HER2/receptor tyrosine kinase
activation, should be investigated in tumors to determine if they
constitute predictive markers of efficacy for pazopanib treatment.
Supporting Information
Figure S1 Kinase assay on cell lysates. Increasing concen-
trations (0.022, 00.22, 2.2 mM) of pazopanib were incubated with
cell lysates for 20 min at 30uC. Inactive MEK1 was added for
30 min and the level of MEK1 phosphorylation was analyzed with
pMEK1 and total MEK1 antibodies. The source of the cell lysate
is indicated under each panel.
(PDF)
Figure S2 Cell viability assay on 231-BR cells with
siRNA-reduced B-Raf expression. 231-BR cells were trans-
fected with two different B-Raf siRNA constructs (S1 and S2), with
a non targeting siRNA (C), or treated with the transfection agent
alone (T). Cells were trypsine and seeded in a 96 h well plates and
6-well plates. At T0, corresponding to 48 h after transfection, cells
were treated with increasing concentrations of pazopanib in the 96
well plate and an MTT assay was performed 96 h later (T96). Cell
lysates were collected (from plates seeded in parallel) at T0 and
T96 to check the level of B-Raf and Tubulin expression. A-
Western blot of B-Raf expression at T0 and T96. Data from one of
three experiments is shown. B- Percent of densitometric ratio B-
Raf/Tubulin compared to the non targeting siRNA control (from
panel A). C- Viability at T96 without any pazopanib treatment
(average of the three experiments). D- Cell viability by MTT assay
at T96 with the indicated Pazopanib treatments.
(PDF)
Figure S3 pERK1/2, pMEK1/2 and pAKT staining in
primary tumors. For each cell line, pERK1/2, pMEK1/2 and
pAKT expression was quantified on five mice per treatment group.
Three photographs of ‘‘hot spot’’ staining per section were used to
quantify the number of positive cells. P values are shown for the markers
that achieved significance at a given dose of pazopanib (P,0.01).
(DOC)
Figure S4 CD31 staining in primary tumors. Five mice
per group and one section per mouse were stained for CD31.
Three photographs of ‘‘hot spot’’ staining were used for
quantification. Panels A and B show representative photographs
of CD31 staining for each tumor (1006 magnification). The
AxioVision4 software was used to quantify the number of blood
vessels per photograph and the percentage of area occupied by
blood vessels, (numbers under each photograph in A and B). The
numbers represent the mean number of vessels 6 SEM in three
‘‘hot spots’’ per section. P values are shown for the markers that
achieved significance at a given dose of pazopanib (P,0.01).
(DOC)
Figure S5 B-Raf siRNA transfection in the 231-BR and
the MCF7-HER2 cell lines. 231-BR (A) and MCF7-HER2 (B)
cell lines were transfected with two different B-Raf siRNA
constructs (S1 and S2), with a non targeting siRNA (C), or treated
with the transfection agent alone (T). Cell lysates were collected at
48, 72 and 96 h after transfection and analyzed by western blot for
B-Raf, Tubulin, PlGF and VEGF expression levels.
(PDF)
Table S1 In vitro growth inhibition of pazopanib on
breast carcinoma and melanoma cell lines by MTT
assay.
(DOC)
Material and Methods S1 B-Raf kinase assay.
(DOC)
Material and Methods S2 B-Raf siRNA transfection
followed by cell viability assay.
(DOC)
Material and Methods S3 DCE-MRI Analysis.
(DOC)
Material and Methods S4 Statistical analysis.
(DOC)
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